Jay Patel, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1518147495
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,368 of the $59,973 with a category attached, or 82.3%. Dexcom, Inc. accounts for 83.6% of it on its own, with 24 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $272.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$50K
- Abbott$7K
- Insulet Corporation$314
- AstraZeneca$287
- Tandem Diabetes Care, Inc.$254
- Lilly USA, LLC$252
- plus $2K from 19 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$49,36882%
- Travel & lodging$3,7446%
- Food & beverage$6,40011%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 106 | $50,109 |
| Abbott | 16 | $7,167 |
| Insulet Corporation | 7 | $314 |
| AstraZeneca | 3 | $287 |
| Tandem Diabetes Care, Inc. | 6 | $254 |
| Lilly USA, LLC | 24 | $252 |
| Cequr Corporation | 2 | $215 |
| BETA Bionics, Inc. | 7 | $171 |
| Novo Nordisk | 14 | $153 |
| Sanofi-aventis U.S. LLC | 3 | $145 |
| Sequel Med Tech, LLC | 1 | $139 |
| Medtronic(2 entities) | 5 | $134 |
| Xeris Pharmaceuticals, Inc. | 7 | $129 |
| Amarin Pharma, Inc. | 1 | $107 |
| Amgen(2 entities) | 5 | $68 |
| Globus Medical | 1 | $56 |
| Amryt Pharma Holdings Ltd | 2 | $53 |
| Nevro Corp. | 1 | $48 |
| Mannkind Corporation | 2 | $36 |
| Corcept Therapeutics | 1 | $36 |
| AbbVie(2 entities) | 2 | $33 |
| Boston Scientific | 1 | $23 |
| Antares Pharma, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Abiomed | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$47,577
- DEXCOM STELO GLUCOSE BIOSENSOR$18,184
- FREESTYLE LIBRE 3$6,938
- DEXCOM G6 TRANSMITTER$474
- FARXIGA$228
- FreeStyle Lite system$150
- TWIIST$139
- CeQur Simplicity$139
- Omnipod$120
- t-slim insulin pump$110
- Vascepa$107
How this compares
$59,973 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 307 | $359,231 |
| TrulicityDulaglutide | 223 | $309,482 |
| JardianceEmpagliflozin | 115 | $147,625 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 156 | $143,164 |
| MounjaroTirzepatide | 90 | $124,633 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 34 | $68,995 |
| FarxigaDapagliflozin Propanediol | 46 | $53,119 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 34 | $48,517 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $43,272 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $31,306 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 178 | $31,060 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $25,923 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $21,781 |
| JanuviaSitagliptin Phosphate | 15 | $19,586 |
| Humulin R U-500Insulin Regular, Human | 12 | $19,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $252 | $447,862389 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $153 | $378,233339 claims |
| AstraZenecaFarxiga | $287 | $53,11946 claims |
| Sanofi-aventis U.S. LLCAdmelog, Lantus | $145 | $8,45938 claims |
| AbbVieSynthroid | $33 | $3,70468 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$2.3M
- Samuel AndersonColumbus$556K
- Ravi DhawaleColumbus$175K
- Laura RyanColumbus$126K
- Kathleen WyneColumbus$88K
- Kathleen DunganColumbus$60K
- Lawrence KirschnerColumbus$57K
- Shrikant TamhaneColumbus$55K
- Constantine KroustosColumbus$53K
- Laura ButzColumbus$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.